Myriad Launches Precision Oncology Suite Following New FDA Approval

Myriad Genetics Inc. is launching a new suite of genetic tests designed for personalizing chemotherapy treatment. The Precise oncology offering includes Myriad’s precise tumor molecular profile test and two companion diagnostic tests, Mychoice CDx and Bracanalysis CDx. The company said the combination of germline, somatic and companion testing aims to maximize information for oncologists as they assign individual treatment plans. Results from each test are gathered as a single report accessed on an online portal.

Source: https://www.bioworld.com/articles/516949-myriad-launches-precision-oncology-suite-following-new-fda-approval?v=preview